Skip to main content

Full text of "USPTO Patents Application 09848616"

See other formats


Drafts 
!• S3 BRS: 
L 3 BRS: 1 and 2 

i Q Pending 

&#[A#ivi; 

^ L1?(1025) (hbv or hepatitis adj b) with parti 
M9L2: (9412) allergen$4 
MS L4: (3) 1 same 2 
; L3: (59) 1 and 2 
r'S L5: (1053045) particl$3 orvlp$1 
i ^ L6: (385) 2 with 5 
i ^ L7: (171) 2 adj5 5 
MS L8: (2561) vIp or virus adj like 
r 39 L9: (6) 2 with 8 
r*S L10: (7) 2 same 8 
r 13 L1 1: (12348) (hbv or hepatitis adj b) 
! 10L12: (43) 2 with 11 
h«L13:(4227)th2 or th adj 2 




(hbv or hepatitis adj b) with parti c$3 



_ 



allergen$4 



1 same 2 
1 fand 2 
particl'$3orvip$1 

2 with 5 
2 adj5 5 

vIp or virus adj like 
2 with '8 
2 same8 



USPAT; USPGPUB; 
EPp;JPp; 



USPAT; US-PGPUB; 



. EPP;. . JPO; DERWENI .08:50 



USPAT; US-PGPUB 

EPP, . JPO; DERWENI 

USPAT; US-PGPUB; 

EPP; JPO; DERWENI.. 

USPAT; US-PGPUB; 

EPP.;. JPO; DERWENI 

USPAT; US-PGPUB; 



(hbv or hepatitis adj b) 



2 with 1 1 



th2 orth adj 2 



13 same 11 



1998-520792.NRAN. 



USPAT; US-PGPUB; 
EPP, JPO;. DERWENI 



USPAT; US-PGPUB; 



EPP; JPO; DERWENI 09:00 .... 



2003/02/03 

09:0Q 

2003/02/03 

0?:Q1 

2003/02/03 

09:01 

2003/02/03 



EPP; JPO; DERWENT 0.9:0.2 



USPAT; US-PGPUB; 



EPO; JPO; ...DERWENI .Q9:02 



USPAT; US-PGPUB; 
EPP,.JPP;.DERWEM. 



USPAT; US-PGPUB; 
EPO;. JPO; DERWENI 



USPAT; US-PGPUB; 
EPP; JPO; D.ERWENT 



USPAT; US-PGPUB; 
EPO;. JPO;... DERWENI. 



USPAT; US-PGPUB; 
EPp;..JPp;DERWENI 



DERWENT 



2003/02/03 
09:03. 



2003/02/03 

08;5Q. 



2003/02/03 



2003/02/03 



2003/02/03 



2003/02/03 
0.9:0.3, 



2003/02/03 
P9:.Q4... 



2003/02/03 

Q9:1.2. 



2003/02/03 

09:1.2.. 



2003/02/03 

Q?:12.. 



2003/02/03 
Q.9:14 





[0984861 6. wsp:1] 



§iiiiiiiP : * : * 



y ^ w :£ i M r t $s 



44 



a Q' Drafts 
i 13 BRS: 



i 3 BRS: 1 and 2 



L ~Cs BRS: cysteine with 1 1 
:© Pending 



! LI: (1025) (hbv or hepatitis adj b) with partic$3Mff 

j IS L2: (9412) allergen$4 Hi 

;~® L4: (3) 1 same 2 

i L3: (59) 1 and 2 

r L5: (1053045) particl$3 orvlp$1 

j % L6: (385) 2 with 5 
i MS L7: (171)2adj5 5 

: 13 L8: (2561 ) vIp or virus adj like 
i h L9: (6) 2 with 8 

j 30L1O: (7) 2 same 8 

!■ L11: (12348) (hbv or hepatitis adj b) 

I- -^S L12: (43) 2 with 11 
_}:.1B L13:..(4227)th^orjh adj 2 



Default operate?:"! ^0R:li.^ : -i :•' : ' v - : HigHight cdl fiit terms 



Wis* 



Hits 



iSeafchlText^ 



DBS: 



13 



14 



1 5. 



16 



18. 



201 



2* 
221 



BRS 
BRS 
BRS 
BRS 
BRS 
BRS 
BRS 
BRS 
BRS 
BRS 



24 r 



25:i 



26j 



m 



BRS 
BRS 
BRS 
BRS 
BRS 
BRS 



;L13 [4227 

1'li4 r|'3i * 

IfamEIT" 

|L18 ' 1208' 
1tl9 15 
"jL20 [2146 
1'L21 ( 10 
"!L22 '. i'37 ." 

■ > i 

IL23 [113 

:L24 1246268 

1 \1 
|L25 |1 

]L26 j92 
|L27 ^'{5433 
128 j464 ~ 

]L30~~jO~ 

1'L29""'~'l277 





th2 orth adj 2 
1 3 same 1 1 

._ : ^^^„_ 

cysteine.! 

if and 18 

cysteine .ti. 

20 'and Ti 

cysteine with 11 

cysteine with depleted 

conjugat$4 or cross or crosslink!^ 

'23 same'24 

'23and'24 

cysteine with (replac$3 or substitut$4) 

27 with 24 

28 same 11 
28and 11 



iUSPAT; US-PGPUB; 
iEPO; JPO; DERWENT 
iUSPAT; USPGPUB; 
lEPO; JPO; DERWENT 

Iderwent 

IUSPAT 
"iUSPAT 

IUSPAT; USPGPUB; 
1EPO; JPO; DERWENT 
iUSPAT; US-'PGPUB; 
lEPO; JPO; DERWENT 
IUSPAT; US-PGPUB; . 
(EPO; JPO; DERWENT 
iUSPAT US-PGPUB; 
lEPO; JPO; DERWENT 
iUSPAT; US-PGPUB; 
(EPO; JPO; DERWENT 
IUSPAT; US-PGPUB;'' 
iEPO, JPO; DERWENT 
jUSPAT; US-PGPUB; 
iEPO; JPO; DERWENT 
iUSPAT; US-PGPUB; 
IEPO; JPO; DERWENT 
jUSPAT; US-PGPUB; 
iEPO; JPO; DERWENT 
iUSPAT; US-PGPUB; 
IEPO; JPO; DERWENT 
jUSPAT; USPGPUB; 
jEPO, JPO; DERWENT 



12003/02/03 

!09:12 

!2603/02/03 

109:12 

S2003/02/03 

109:14 

!2b03/b2/03 

109:47 

12003/02/63 

h0:00 

12003/02/03' 

109:49 

12003/02/03 

!09:48 

12003702/03 

109:49 

(2003762703 

(10:07 

12003/02703 

i 10:02 

(2003702/03 

(10:02 

12003/02/03 

110:02 

12003/02703 

110:08 

52003/02/03 

110:09 

12003702/03 

(10:09 

12003702/03 

110:09 



EAST - [0984861G.wsp:1] 





































B 


M 




n 




if 


w 


M 













a Drafts i 
! S3 BRS: 

1 3 BRS: 1 and 2 I 
| 0 Pending ;j 
& Active ! 

I'-'S L1: (940578) conjugat$4 or crosslink$4 or link: 

MB L2: (408) (hbcag or hbsag) same 1 
; L -S9 L3: (234) (hbcag or hbsag) with 1 
<M£ Failed 

! (0) s 13 and 14 
j (0) 7 with 8 1 
9 ~g| Saved 

j £ (31) FORMAT ADJ SAVE 

r IS (31) molecular adj antigen I 

i HQ (106) bachmann-m$.in. f 

j 10 (6922) hepatitis adj b or hbv 

!• 12 (258450) core or nucleocapsid or hbcag if 

i "§9 (2209) (hepatitis adj b or hbv) and (core or nucf; 

f-« (1176) hbsag 

j- '® (1837627) hbsag or surface 

j~ "S9 (940578) conjugat$4 or crosslink^ or link$4 c 

1 "SS (24189) (core or nucleocapsid or hbcag) with (t 

;• S Favorites 



<J 



i.. 



|tt BRS 



Document ID 



Title 



IsisuelDaie 



IhvSntdrl 



F 



2 



3 . 



4 . 



5 



WO ^Composition for use as vaccine against infectious 

200032227 A idiseases and in treatment of cancer and allergies 
IWO 2056905 MOLECULAR ANTTIGEN ARRAY 

IA2 | 

WO Molecular antigen array used in the production of 

200256907 A jvaccines for infectious diseases 

iWO ^Molecular antigen array used in the production of 

; [200256905 A jvaccines for infectious diseases 

[WO (New composition, useful for vaccine production, 

1200185208 A (comprises antigen or antigenic determinant and 
^ [US 5324513 A|Composition useful for the fabrication of vaccines;" 



F 

F i 

F 

F 



:20000608 
j 20020725 
|20020725 
120020725 
12001 11 15 

119940628" 



IBACHMANN, Metal. 



! US 6231 864 j Strategically modified hepatitis [2001051 5 

: |B1 ^derivatives 



F 



iUS 6355414 llmmunopotentiating formulations for vaccinal use 

!B1 ! 



9 



|20020312 

I 

120020917' 



IRENNER, 

:WOLFGANG Aetal. ; 

j B ACHM ANN^ M et all "| 

jBACHMANNyMetaL! 

IB ACHM ANN; M elaU 

j Sobc2ak"B ane et ai7j424/| 

•BirtetT Ashley j" -424/1 

jCesaretal. 

jStephenne, Jean et aij424?J 



IB! 



„ jUS 6451320 ICombined hepatitis and herpesvirus antigen 
: jB1 (compositions 
jUS 5039522 A jlmmunogens containing peptides with an attached 119910813 nNeurathrA 
ihydrophobic tail for adsorption to hepatitis B virus surface I 



•T 555 HTML 



18/7/1 

DIALOG(R)File 155 :MEDLINE(R) 



13927589 22153991 PMID: 12163261 

A molecular assembly system that renders antigens of choice highly 
repetitive for induction of protective B cell responses. 

Jegerlehner Andrea; Tissot Alain; Lechner Franziska; Sebbel Peter; 
Erdmann Iris; Kundig Thomas; Bachi Thomas; Storni Tazio; Jennings Gary; 
Pumpens Paul; Renner Wolfgang A; Bachmann Martin F; et al 

Cytos Biotechnology AG, CH-8952 Schlieren-Zurich, Switzerland. 

Vaccine (England) Aug 19 2002, 20 (25-26) p3 104-12, ISSN 0264-410X 
Journal Code: 8406899 

Document type: Journal Article 

Languages: ENGLISH 

Main Citation Owner: NLM 

Record type: In Process 

Virus like particles (VLPs) are known to induce potent B cell responses 
in the absence of adjuvants. Moreover, epitope-specific antibody responses 
may be induced by VLPs that contain peptides inserted in their 
immunodominant regions. However, due to steric problems, the size of the 
peptides capable of being incorporated into VLPs while still permitting 
capsid assembly, is rather limited. While peptides genetically fused to 
either the N- or C-terminus of VLPs present fewer assembly problems, the 
immune responses obtained against such epitopes are often limited, most 
likely because the epitopes are not optimally exposed. In addition, such 
particles may be less stable in vivo. Here, we show that peptides and 
proteins engineered to contain a free cys can be chemically coupled to VLPs 
formed from the hepatitis B core antigen (HBcAg) containing a lys in the 
immuno-dominant region. By using this approach steric hindrance of capsid 
assembly is abrogated. Peptides or protein coupled to VLPs in an oriented 
fashion are shown to induce strong and protective B cell responses even 
against self-epitopes in the absence of adjuvants. This molecular assembly 
system may be used to induce strong B cell responses against most antigens. 
Copyright 2002 Elsevier Science Ltd. 

Record Date Created: 20020806 



18/7/3 

DIALOG(R)File 1 5 5 :MEDLINE(R) 
10853039 20404849 PMID: 10949916 

Insertion of foreign epitopes in HBcAg: how to make the chimeric particle 
assemble. 

Karpenko L I; Ivanisenko V A; Pika I A; Chikaev N A; Eroshkin A M; 
Veremeiko T A; Ilyichev A A